Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Cowellnex
Deal Size : Undisclosed
Deal Type : Agreement
Siolta Therapeutics and Cowellnex Enter Joint Research Agreement
Details : Under the agreement, Siolta will develop live biotherapeutic products with joint research program with Cowellnex for treating necrotizing enterocolitis in infants.
Product Name : Undisclosed
Product Type : Microorganism
Upfront Cash : Undisclosed
January 29, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Cowellnex
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : NIDCR
Deal Size : $2.2 million
Deal Type : Funding
Sinopia Gets SBIR Phase II Grant For Oral Mucositis Research
Details : The funding aims to support the company in discovering novel small molecules and identifying promising treatment candidates for oral mucositis.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : NIDCR
Deal Size : $2.2 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
SNIPR Biome Receives Funding for CRISPR-Medicines to Improve EED in Pregnant Women
Details : The funding from the Bill & Melinda Gates Foundation will be used to develop a microbiome-directed intervention designed to improve EED by reducing gut entero-pathogen burden in pregnant women.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 28, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Bill & Melinda Gates Foundation
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Sonoma Biotherapeutics Receives $45M Regeneron Milestone
Details : The collaboration will bring together Regeneron’s VelociSuite technologies to discover, develop and commercialize engineered Treg therapies for autoimmune diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $75.0 million
April 09, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Regeneron Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the collaboration, Ferring will get exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 12, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Ferring Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal diseases.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Verily’s proprietary Immune Profiler is a next generation immune mapping platform that will be used to identify GPCR targets that represent new opportunities to modulate immune cell function and ameliorate disease pathology.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The collaboration will support Sanofi’s use of CytoReason’s computational disease models to develop new targets for inflammatory bowel disease (IBD), to identify patient subtypes and pair them with IBD targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Sanofi
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Agreement
Details : The focus of the agreements is to apply the innovative technologies and research capabilities of the respective academic groups to identify, validate and prioritize key GPCRs driving gastrointestinal and immune disorders, including IBD, as targets for SB...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 12, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : University of Oxford
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The agreement will leverage Sosei Heptares’ GPCR Diversified Compound Library and GPCR expertise with the innovative Kallyope gut-brain axis platform, which combines single-cell sequencing, circuit mapping, computational biology and enteroid phenotypic...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 17, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Collaboration